Fundamental Analysis of Oncternal Therapeutics Inc - Growth / Value Index


ONCT - Valuation Highlights

Valuation Analysis

   Price to Book Ratio is 0.680 indicating that it is undervalued.
   Tsr Value Index - Poor Score of 25.00
   Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -0.746 -0.649 -18.38 %
Price to Book 0.723 0.901 126.82 % 1.19
Price to Sales 23.59 34.49 112.21 %
Enterprise Value to EBITDA Multiple -0.541 -0.493 -269.84 %


ONCT - Profitability Highlights

Profitability Analysis

   Company's Net Profit is increasing for last 5 Quarters
   Company's Profit Before Tax is increasing for last 5 Quarters
   Steady Growth in EPS for last four quarters
   Tsr Profitability Index - Very Poor Score of 5.00
   Piotroski F Score - Very Poor Value of 1.0
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
   Negative Net Margin MRQ
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity -96.94 -138.81 -91.60 % -36.59
Return On Asset -83.39 -113.58 -76.52 % -28.78
Net Profit Margin -3160.73 -5314.01 -79.26 % -1474.17
Operating Profit Margin -3331.89 -5604.20 -85.78 % -1542.88
EBITDA Margin -3331.89 -5314.01 -78.96 % -1542.88


Highlights
Market Cap27258.28 K
Enterprise Value20734.28 K
Price/Book TTM0.723
Outstanding Share2959.64 K
Float/ Outstanding Share91.42%
Dividend Yield2.12 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score1.00
Altman Z Score-7.81
Sloan Ratio-0.190
Peter Lynch Fair Value0


ONCT - Growth Highlights

Growth Analysis

   Short term positive trend in total sale and net profit
   YoY Net Margin Jump by 79.26%
   Quarterly sales in last 5 years is trending up
   Tsr Growth Index - Poor Score of 34.14
   Annual sales in last 3 years is trending down
   Companies' sales dropped by 47.32 % from last year
   Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 1151.00 K 47.32 % 91.58 %
Gross Profit 1039.00 K 47.32 % 91.58 %
EBITDA -38350.00 K 5.72 % 8.89 %
Net Profit -36380.00 K 5.56 % 8.47 %
EPS -12.34 15.53 % NA


ONCT - Stability Highlights

Stability Analysis

   Cash ratio of 6.59
   Altman Z Score of -7.95 suggest high risk
   Company's debt has increased with decreasing revenue.
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of 0
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.0058 303.42 % 0.0078
Cash Ratio 6.59 -20.56 %
Quick Ratio 6.94 -20.68 % 4.66
Shareholders Equity 81.82 -7.87 %
Debt to EBITDA -0.0041 -110.91 %


Historical Valuation Ratios of Oncternal Therapeutics Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Oncternal Therapeutics Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Oncternal Therapeutics Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Oncternal Therapeutics Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)